XNCR Stock Summary and Trading Ideas (Xencor | NASDAQ:XNCR)

Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

Xencor trades on the NASDAQ stock market under the symbol XNCR.

As of January 30, 2026, XNCR stock price declined to $12.09 with 534,910 million shares trading.

XNCR has a beta of 1.61, meaning it tends to be more sensitive to market movements. XNCR has a correlation of 0.15 to the broad based SPY ETF.

XNCR has a market cap of $862.30 million. This is considered a Small Cap stock.

Last quarter Xencor reported $21 million in Revenue and -$.08 earnings per share. This fell short of revenue expectation by $-6 million and exceeded earnings estimates by $.63.

In the last 3 years, XNCR traded as high as $38.20 and as low as $6.92.

The top ETF exchange traded funds that XNCR belongs to (by Net Assets): IJR, VTI, XBI, IWM, VB.

XNCR has underperformed the market in the last year with a price return of -34.6% while the SPY ETF gained +15.6%. XNCR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -14.4% and -5.5%, respectively, while the SPY returned +2.1% and 0.0%, respectively.

XNCR support price is $11.87 and resistance is $12.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XNCR shares will trade within this expected range on the day.